Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q1 EPS of ($0.36), in-line with the analyst estimate of ($0.36). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $6.73 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.